Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia

@article{Lemoine2012ProlongedreleaseFO,
  title={Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia},
  author={Patrick Lemoine and Nava Zisapel},
  journal={Expert Opinion on Pharmacotherapy},
  year={2012},
  volume={13},
  pages={895 - 905}
}
  • P. LemoineN. Zisapel
  • Published 21 March 2012
  • Medicine, Psychology, Biology
  • Expert Opinion on Pharmacotherapy
Introduction: Insomnia is common among the elderly. The use of hypnotic drugs in elderly patients is frequently criticized owing to dependency, cognitive impairments, falls and withdrawal effects. The production of melatonin, a physiological sleep and circadian rhythm regulator, declines with age. Prolonged-release melatonin (Circadin®), designed to mimic the endogenous pattern of melatonin production, is licensed for insomnia in patients aged ≥ 55 years. Areas covered: This review summarizes… 

Current Phase II investigational therapies for insomnia

  • N. Zisapel
  • Biology
    Expert opinion on investigational drugs
  • 2015
This review summarizes the available efficacy and safety data for drugs currently in the pipeline for treating insomnia and indicates that new insomnia therapies will most likely move away from GABAAR receptors’ modulation to more subtle neurological pathways that regulate the sleep–wake cycle.

Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial

Nightly use of prolonged-release melatonin (PRM) may potentially improve patient-reported sleep difficulties in totally blind individuals trying to adhere to normal social lifestyle and may allow early decision-making on further drug development in this indication.

Safety of melatonin

  • N. Zisapel
  • Medicine
    Journal of paediatrics and child health
  • 2015
The author raised relevant questions on the use of melatonin for sleep in children and mainly cautioned its safety in this population, and regretfully and without justification wrapped-up Circadin (Prolonged-release melatonin, RAD-Neurim Pharmaceuticals EEC), a prescription-only drug intended to mimic the endogenous secretion ofmelatonin, with unlicensed products.

Possible Role of Exogenous Melatonin and Melatonin-Receptor-Agonists in the Treatment of Menopause―Associated Sleep Disturbances

The currently available evidence regarding the effects of these compounds on sleep quality and their possible use in menopause associated sleep disturbances is presented.

Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 – 2014)

A major trend in 2012 – 2014 patents is the co-administration of melatonin with other drugs to increase the efficacy of the treatment and reduce side-effects, and two different actions have been combined in hybrid ligands.

Melatonin, temazepam and zolpidem effects on sleep Page 1 of 29 Randomized clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people

The data show that the effects of prolonged-release melatonin on the nocturnal sleep EEG are minor and are different from those of temazepam and zolpidem; this is likely due to the different mechanisms of action of the medications.

Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people

The data show that the effects of prolonged-release melatonin on the nocturnal sleep EEG are minor and are different from those of temazepam and zolpidem; this is likely due to the different mechanisms of action of the medications.

Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders

The review underlines the beneficial value of enhancing physiological sleep in comorbid conditions and the efficacy and safety profiles of melatonin receptors agonists in the treatment of insomnia, depression and circadian rhythms sleep-wake disorders.

Sleep Disorders in Postmenopausal Women.

More potent melatonin analogs with prolonged effects and slow-release melatonin preparations have been developed and were found effective in increasing total sleep time and sleep efficiency as well as in reducing sleep latency in insomnia patients.
...

References

SHOWING 1-10 OF 139 REFERENCES

Prolonged-release melatonin for the treatment of insomnia: targeting quality of sleep and morning alertness

Prolonged-release (PR) melatonin (Circadin ®, Neurim Pharmaceuticals, Tel-Aviv, Israel) is a nonbenzodiazepine licensed to treat primary insomnia in patients aged 55 years and older and has been shown to be effective in improving quality of sleep and morning alertness.

[Controlled release melatonin (Circadin) in the treatment of insomnia in older patients: efficacy and safety in patients with history of use and non-use of hypnotic drugs].

Analyses presented here show that Circadin has comparable efficacy and safety in patients with and without history of hypnotic drug use, and is used concomitantly with most medications but may potentiate the effects of GABA-A receptor modulators.

Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes

PR-melatonin results in significant and clinically meaningful improvements in sleep quality, morning alertness, sleep onset latency and quality of life in primary insomnia patients aged 55 years and over.

Melatonin replacement therapy of elderly insomniacs.

It is suggested that for melatonin-deficient elderly insomniacs, melatonin replacement therapy may be beneficial in the initiation and maintenance of sleep.

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety

The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients and low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia.

Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response

Short- and long-term efficacy of PRM in insomnia patients aged 18–80 years, particularly those aged 55 and over are demonstrated, and PRM was well-tolerated over the entire 6-month period with no rebound or withdrawal symptoms following discontinuation.

Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal

Results support the efficacy and safety of PRM in primary insomnia patients aged 20–80 throughout 6–12 months of continuous therapy.

Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy.

Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database

Based on the observed 31% discontinuation rate, PR melatonin may help to facilitate BZD/Z discontinuation in older insomniacs.
...